Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 9/20 | 0.40 |
| ▸ | ABL1 | P00519 | 5/20 | 0.40 |
| ▸ | SRC | P12931 | 4/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410098 | 0.83 | TNK2 (0.52) | BTKTNK2ABL1SRCTLR7 | |
| SCHEMBL463424 | 0.79 | BTK (0.50) | BTKIGF1RTNK2ABL1SRC | |
| SCHEMBL23044547 | 0.76 | BTK (0.48) | BTKIGF1RTNK2ABL1SRC | |
| SCHEMBL12165128 | 0.76 | BTK (0.51) | BTKIGF1RTNK2ABL1SRC | |
| SCHEMBL13201547 | 0.76 | BTK (0.48) | BTKIGF1RTNK2ABL1SRC | |
| SCHEMBL24696960 | 0.75 | BTK (0.47) | BTKIGF1RTNK2ABL1SRC | |
| SCHEMBL23960263 | 0.73 | BTK (0.46) | BTKIGF1RTNK2ABL1SRC | |
| SCHEMBL2618928 | 0.73 | TNK2 (0.52) | BTKIGF1RTNK2ABL1SRC | |
| SCHEMBL13077692 | 0.70 | RET (0.40) | RETKDR | |
| SCHEMBL14490306 | 0.70 | BTK (0.66) | BTKIGF1RTNK2ABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912980-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | Minghui Pharmaceutical (Shanghai) Limited (CN) | 2021-11-24 | — | — | EP | disclosed |
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | PHARMACYCLICS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-7825118-B2 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | BTK, LCK, LYN | BTK 1/4885IGF1R 1738/4885TNK2 276/4885 |
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | BTK, ABL1, LYN | BTK 1/4885IGF1R 1124/4885TNK2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.